

CUMULATIVE INDEX Psychopharmacology Bulletin

A. Contents Index
Vol. 29, No. 1—1993

NCDEU Symposia (1992 Meeting)

Design and Methodology Issues for Clinical Treatment Trials in Children and Adolescents

- 3 Nurturing a Vigorous Methodology For
Child and Adolescent Treatment
Research—*L. Eugene Arnold*
- 5 A Comparative Overview of Treatment
Research Methodology: Adult vs. Child
and Adolescent, Psychopharmacological
vs. Psychosocial Treatments—*L. Eugene
Arnold*
- 19 Development and Implementation of
Multimodal and Combined Treatment
Studies in Children and Adolescents:
NIMH Perspectives—*Peter S. Jensen*
- 27 Psychosocial Treatment Research With
Children and Adolescents: Methodological
Issues—*Euthymia D. Hibbs*
- 35 Challenges in Medication Clinical Trials—
Matthew V. Rudorfer

Assessing Negative Symptoms and Extrapyramidal Symptoms in Schizophrenia

- 45 Assessing Negative Symptoms and Extrapy-
ramidal Side Effects in Schizophrenia:
Workshop Report—*John M. Kane,
Deborah Dauphinais, Thomas R.E.
Barnes, Lenard A. Adler, and Arthur
Rifkin*

Postmarketing Surveillance of Psychotherapeutic Medications: A Challenge for the 1990's

- 51 Differences in Adverse Drug Reactions
in Phase III and Phase IV of the Drug
Evaluation Process—*Michael Linden*

The Clinical Psychopharmacology of Violence

- 57 Toward a Nosology of Human Aggressive
Behavior—*Burr Eichelman and
Anne Hartwig*
- 65 The Psychopharmacology of Aggression:
Toward a New Day—*John J. Ratey and
Amy Gordon*
- 75 The Use of Anticonvulsants in Aggression
and Violence—*Ernest S. Barratt*

Diagnosis and Treatment of Depression in Late Life

- 83 The NIH Consensus Development Confer-
ence on the Diagnosis and Treatment of
Depression in Late Life: An Overview—
*Charles F. Reynolds III, Barry D.
Lebowitz, and Lon S. Schneider*
- 87 Diagnosis and Treatment of Depression in
Late Life: The NIH Consensus Develop-
ment Conference Statement
- 101 Drug Treatment of Depression in the Frail
Elderly: Discussion of the NIH Consensus
Development Conference on the Diagnosis
and Treatment of Depression in Late
Life—*Ira R. Katz*

Bulimic Disorders: Pharmacotherapeutic and Biological Studies

- 109** Overview of the Definition, Prevalence, and Comorbidity of Bulimic Disorders—*Harry E. Gwirtsman*
- 115** Antidepressants vs. Psychotherapy in the Treatment of Bulimia Nervosa—*David W. Abbott and James E. Mitchell*
- 121** Bulimia Nervosa: Comparison of Treatment Responders vs. Nonresponders—*David B. Herzog and Natalie R. Sacks*

Dual Diagnosis/Psychiatric Comorbidity of Drug Dependence: Epidemiology and Treatment

- 127** Adjunctive Imipramine in Substance-Abusing Dysphoric Schizophrenic Patients—*Samuel G. Siris, Susan E. Mason, Paul C. Bermanzohn, Mitchell A. Shuwall, and Mary Anne Aseniero*

Commentary

- 135** Postmarketing Surveillance: Perspectives of a Journal Editor—*Alan J. Gelenberg*

Psychopharmacology—A Recurring Bibliography

Vol. 29, No. 2—1993

NCDEU Posters and Free Communications— 1992 Annual Meeting

- 141 Selecting an Interim Analysis Procedure—
John E. Overall and Robert S. Atlas
- 149 Central Serotonergic Changes Following
Antidepressant Treatment: A Neuroendo-
crine Assessment—*Martha E. Leatherman,
R. David Ekstrom, Mark Corrigan, Stanley
W. Carson, George Mason, and Robert N.
Golden*
- 155 Fenfluramine Challenge Test as a Predictor
of Outcome in Major Depression—*Kevin
M. Malone, Michael E. Thase, Tammy
Mieczkowski, Joyce E. Myers, Stacy D.
Stull, Thomas B. Cooper, and J. John Mann*
- 163 Effect Size as a Measure of Symptom-
Specific Drug Change in Clinical Trials—
*Andrew C. Leon, M. Katherine Shear,
Laura Portera, Gerald L. Klerman*
- 169 Efficacy and Safety of b.i.d. Doses of
Venlafaxine in a Dose-Response Study—
*Joseph Mendels, Robert Johnston, Jeffrey
Mattes, and Robert Riesenber*
- 175 A Quantitative Analysis of Clinical Drug
Trials for the Treatment of Affective
Disorders—*John M. Davis, Zhengyu
Wang, and Philip G. Janicak*
- 183 Preliminary Report: Placebo-Controlled,
Double-Blind Study of the Clinical and
Metabolic Effects of Desipramine in Panic
Disorder—*R. Bruce Lydiard, W. Alex
Morton, Naresh P. Emmanuel, Joseph J.
Zealberg, Michele T. Laraia, Gail W.
Stuart, Patrick M. O'Neil, and James C.
Ballenger*
- 189 A Three-Generational Presentation of
Separation Anxiety in Childhood With
Agoraphobia in Adulthood—*Joseph A.
Deltito and Richard Hahn*
- 195 Fluoxetine Trial in Suicidal Depressed
Alcoholics—*Jack R. Cornelius, Ihsan M.
Salloum, Marie D. Cornelius, James M.
Perel, Michael E. Thase, Joan G. Ehler,
and J. John Mann*
- 201 Increases in Heart Rate Variability With
Successful Treatment in Patients With
Major Depressive Disorder—*Scott Balogh,
Denis F. Fitzpatrick, Shelton E. Hendricks,
and Stephen R. Paige*
- 207 Pergolide: An Antidepressant Adjuvant for
Mood Disorders?—*Anthony Bouckoms
and Lynn Mangini*
- 213 Divalproex Sodium Treatment in Late
Adolescent and Young Adult Acute
Mania—*George Papatheodorou and
Stan P. Kutcher*
- 221 Plasma Beta-Endorphin Levels,
Naltrexone, and Haloperidol in Autistic
Children—*Monique Ernst, Lakshmi Devi,
Raul R. Silva, Nilda M. Gonzalez, Arthur
M. Small, Richard P. Malone, and Magda
Campbell*
- 229 Mismatch Negativity in Hyperactive
Children: Effects of Methylphenidate—
*Bertrand G. Winsberg, Daniel C. Javitt,
Gail Shanahan Silipo, and Paolina
Doneshka*
- 235 Pharmacologic Relationship of Antisaccade
and Dyskinesia in Schizophrenic Patients—
*Shawn L. Cassidy, Gunvant K. Thaker,
and Carol A. Tamminga*

- 241** Psychotherapeutic Medications Development Program (PMDP)—*Henry J. Haigler, Jerry M. Cott, Matthew V. Rudorfer, Ronald I. Schoenfeld, William Z. Potter, Benedetto Vitiello, and Hilleary D. Everist*
- 249** Thioridazine Improves Affective Symptoms in Schizophrenic Patients—*Robert L. Dufresne, Dominic Valentino, and David J. Kass*
- 257** High Plasma Clozapine Levels in Tardive Dyskinesia—*Simcha Pollack, Jeffrey Lieberman, Deborah Kleiner, Sally Szymanski, John Kane, Michael Borenstein, and Thomas Cooper*
- 263** Factor Stationarity and Invariance of the POMS in Cocaine Patients—*Howard M. Rhoades, John Grabowski, Ronith Elk, and Kathy Cowan*
- 269** Stabilization and Depot Neuroleptic Doses—*Peter Weiden, Nina R. Schooler, Joanne B. Severe, J. Hillary Lee, and S. Charles Schulz*
- 277** Plasma Gamma-Aminobutyric Acid (GABA) is Low in Alcoholics—*Frederick Petty, Mark Fulton, Frederick G. Moeller, Gerald Kramer, LeAnn Wilson, Kathryn Fraser, and Patricia Isbell*
- 283** A Controlled Comparison of the Effects of Propranolol, Benztropine, and Placebo on Akathisia: An Interim Analysis—*Lenard A. Adler, Eric Peselow, Michel Rosenthal, and Burt Angrist*
- 287** Haloperidol Withdrawal and Weight Changes in Autistic Children—*Raul R. Silva, Richard P. Malone, Lowell T. Anderson, Judith Shay, and Magda Campbell*
- 293** Psychobiological Correlates of Poor Response to Cognitive Behavior Therapy: Potential Indications for Antidepressant Pharmacotherapy—*Michael E. Thase, Anne D. Simons, and Charles F. Reynolds III*
- 303** The Safety and Efficacy of Ipsapirone vs. Lorazepam in Outpatients With Generalized Anxiety Disorder (GAD): Single Site Findings from a Multicenter Trial—*Neal R. Cutler, John J. Sramek, Thomas S. Wardle, Jan M. Keppel Hesselink, and Julie K. Roeschen*
- 309** Treatment of Neuroleptic-Resistant Schizophrenic Relapse—*Bruce J. Kinon, John M. Kane, Celeste Johns, Robert Perovich, Mimi Ismi, Amy Koreen, and Peter Weiden*
- 315** Systematic Dosage Reduction in Treatment-Resistant Schizophrenic Patients—*Theodore Van Putten, B.D. Marshall, Robert Liberman, Jim Mintz, Timothy G. Kuehnell, Linda Bowen, Manickam Aravagiri, and Stephen R. Marder*
- 321** Quality of Life Enjoyment and Satisfaction Questionnaire: A New Measure—*Jean Endicott, John Nee, Wilma Harrison, and Richard Blumenthal*
- 327** Nortriptyline in the Hospitalized Elderly: Tolerance and Side Effect Reduction—*Jules Rosen, Robert Sweet, Bruce G. Pollock, and Benoit H. Mulsant*
- 333** Haloperidol vs. Phenelzine in Continuation Therapy of Borderline Disorder—*Jack R. Cornelius, Paul H. Soloff, Anselm George, Richard F. Ulrich, and James M. Perel*

Psychopharmacology—A Recurring Bibliography

Vol. 29, No. 3—1993

Guest Editorial

- 341** Chlorpromazine Turns Forty—*Philip Mitchell*

Selected ACNP Proceedings
1992 Annual Meeting

- 345** ECT and TRH: Cholinergic Involvement in a Cognitive Deficit State—*Arifulla Khan, Mary Helen Mirolo, Henry Lai, Keith Claypoole, Laura Bierut, Rubina Malik, and June Bhang*
- 353** Autistic Children on Followup: Change of Diagnosis—*Nilda M. Gonzalez, Murray Alpert, Judith Shay, Magda Campbell, and Arthur M. Small*
- 359** Neuroleptic-Related Dyskinesias and Stereotypies in Autistic Children: Video-taped Ratings—*Judith Shay, Laura E. Sanchez, Jeanette E. Cueva, Jorge L. Armenteros, John E. Overall, and Magda Campbell*
- 365** Possible Predictors of Neuroleptic-Resistant Schizophrenic Relapse: Influence of Negative Symptoms and Acute Extrapyramidal Side Effects—*Bruce J. Kinon, John M. Kane, Miranda Chakos, and Rafael Munne*
- 371** Vitamin E in Tardive Dyskinesia: Time Course of Effect After Placebo Substitution—*Lenard A. Adler, Eric Peselow, Erica Duncan, Michel Rosenthal, and Burt Angrist*
- 375** Chronic Neuroleptic Use in Manic-Depressive Illness—*Michael J. Sernyak and Scott W. Woods*

- 383** The Effect of Carbamazepine on the White Blood Cell Count in Cocaine Abusers—*James A. Halikas, Sean M. Nugent, Victoria L. Pearson, Ross D. Crosby, Gregory Carlson, and Fred Crea*
- 389** Monoamines and the Mechanism of Antidepressant Action: Effects of Catecholamine Depletion on Mood of Patients Treated With Antidepressants—*Pedro L. Delgado, Helen L. Miller, Ronald M. Salomon, Julio Licinio, George R. Heninger, Alan J. Gelenberg, and Dennis S. Charney*
- 397** Attenuation of Food-Restriction-Induced Running by Chronic Fluoxetine Treatment—*Margaret Altemus, John R. Glowa, and Dennis L. Murphy*
- 401** Neuroanatomical Differences in the Rate of Beta-Adrenergic Receptor Adaptation After Repeated Treatment With Imipramine—*Gary E. Duncan, Ian A. Paul, and George R. Breese*
- 409** Oxytocin and Complex Social Behavior: Species Comparisons—*James T. Winslow, Lawrence Shapiro, C. Sue Carter, and Thomas R. Insel*
- 415** Concentration and Distribution of [³H]-SCH23390 and [³H]-YM09151-2 Binding Sites in Midgestational Human Fetal Cortex—*Alan S. Unis*

Psychopharmacology—A Recurring
Bibliography

Vol. 29, No. 4—1993

**The Value of Psychiatric Treatment:
Its Efficacy in Severe Mental
Disorders**

- 427** Introduction—*Samuel J. Keith and Susan M. Matthews*
- 431** The Clinical Research Base for the Treatment of Schizophrenia—*Nina R. Schooler and Samuel J. Keith*
- 447** Report on Efficacy of Treatments for Bipolar Disorder—*Alan J. Gelenberg and Heather Stone Hopkins*
- 457** Efficacy of Treatments for Major Depression—*Ellen Frank, Jordan F. Karp, and A. John Rush*
- 477** Panic Disorder: Efficacy of Current Treatments—*James C. Ballenger*

- 487** Obsessive-Compulsive Disorder: Efficacy of Specific Treatments as Assessed by Controlled Trials—*Michael A. Jenike*
- 501** Efficacy of Treatment for Geropsychiatric Patients With Severe Mental Illness—*Lon S. Schneider*
- 525** Treatment of Psychiatric Disorders in Children and Adolescents—*Rachel G. Klein and Cheryl Slomkowski*
- 537** Psychiatric Rehabilitation—*Charles J. Wallace*

Cumulative Index—Psychopharmacology Bulletin—1993

Contents Index
Author Index

